Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that sometimes cause impaired decision-making and poor ... Some Diabetes Drugs Tied to ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...

A study reveals that smartwatch data can predict psychiatric illnesses, uncover genetic links, and improve treatment options, ...

A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

People with diabetes are twice as likely to develop heart disease or a stroke compared to people without diabetes. Over time, uncontrolled blood glucose levels can damage your blood vessels. Heart ...

This review provides insights into the pathophysiology of Parkinson’s disease, highlighting the mechanisms of neurodegeneration, the role of alpha-synuclein, and the disruption of dopaminergic ...

In our January research highlights, we look at new research into how AI-powered screening could spot type 2 diabetes risk years in advance, and a new study into genetically altered beta cell therapy ...

Fox Foundation For Parkinson ... treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new ...